Type 2 diabetes medicine widely used since 1922 may affect blood sugar patient's brain, claims recent study

Metformin has been one of the most familiar names in the treatment of type 2 diabetes, primarily recognized for its ability to help control elevated blood glucose. But new research is encouraging scientists to look beyond the liver and digestive system to understand exactly how this long-established medicine works. A study published in Science Advances in 2025 suggests that metformin may also influence blood-sugar regulation through a pathway in the brain, adding an unexpected dimension to a medicine that has been used clinically for more than 60 years. The finding does not mean metformin is a new brain medicine, nor does it show that patients are being harmed. Instead, it highlights how much scientists may still have to learn about a drug that has been part of diabetes treatment for generations.

Metformin has a remarkably long scientific history. The compound was first synthesized in 1922, although its modern role in diabetes treatment emerged much later. Over the decades, it became a cornerstone of type 2 diabetes management because of its glucose-lowering effects, relatively long clinical history, affordability, and established place in treatment. Traditionally, researchers have understood one of its major actions as reducing the amount of glucose released by the liver while helping the body use insulin more effectively. The new findings suggest that explanation may not tell the whole story, as per Science Alert report.

Type 2 Diabetes Research


The researchers from Baylor College of Medicine became interested in the brain because the nervous system plays a major role in regulating metabolism throughout the body. Neurobiologist and pathophysiologist Makoto Fukuda and colleagues investigated whether metformin could influence glucose regulation through a specific region of the brain. Their work focused on the ventromedial hypothalamus, or VMH, an area involved in metabolic control. Earlier research from the group had identified a protein called Rap1 as an important regulator of glucose metabolism in this region.

Experiments in mice produced the study's most intriguing observations. Researchers found evidence that metformin could reach the VMH and influence Rap1 activity. When the animals lacked Rap1, metformin no longer produced the same effect on a diabetes-like metabolic condition, suggesting that this pathway may be important to the medicine's action. The scientists also identified a group of neurons known as SF1 neurons that became active when metformin was introduced into the brain. These findings point toward a previously underappreciated connection between the drug and neural regulation of blood sugar.

The discovery is significant because it adds another possible piece to the complicated puzzle of glucose regulation. For years, discussions about metformin have focused heavily on its effects outside the brain, particularly its influence on liver glucose production. The new study indicates that the brain may be another important component, potentially showing that metformin's overall impact results from several interconnected biological systems rather than one simple mechanism.

One particularly interesting observation was that the brain appeared to respond to lower concentrations of metformin than those required by some peripheral tissues. According to the researchers, this difference could eventually help scientists understand how the medicine produces its metabolic effects and whether particular neural pathways could be targeted more precisely in future therapies. Such possibilities remain speculative, however, because the key experiments were conducted in mice. More research is needed to establish how directly these findings translate to people taking metformin for type 2 diabetes.

Type 2 Diabetes Medicine

The findings also challenge an older assumption about how metformin works. The drug has traditionally been associated with AMP-activated protein kinase, commonly known as AMPK, a cellular energy-sensing enzyme. Over time, however, research has shown that metformin's biological effects are more complicated than a single pathway can explain. The new brain-focused research adds another potential mechanism to that evolving picture and could encourage scientists to revisit how metabolic medicines interact with different organs.

Importantly, the study should not be interpreted as evidence that metformin is damaging the brains of people with diabetes. The research actually investigated a potentially beneficial mechanism for lowering blood glucose. Headlines suggesting that the medicine simply “affects the brain” can therefore be misleading without context. The finding means researchers have identified evidence of brain involvement in glucose regulation, not that patients should fear the medication or change their treatment independently.

This distinction matters because metformin remains an established medication for type 2 diabetes, and patients should not stop or alter prescribed treatment because of a preliminary research finding. Medication decisions depend on an individual's medical history, kidney function, other treatments, blood glucose levels, and advice from a qualified healthcare professional. The new research is primarily important for scientists seeking to understand the biology behind an extremely widely used drug.

Blood Sugar Drug

The discovery could nevertheless have important long-term implications. If future human studies confirm that the brain pathway plays a meaningful role in metformin's glucose-lowering effects, researchers may be able to develop treatments that act more selectively on the neurons and molecular systems involved. Instead of viewing diabetes solely as a problem involving blood sugar and organs such as the pancreas or liver, medicine could increasingly examine the brain's role in controlling whole-body metabolism.

The study also illustrates a broader truth about medical science: familiar medicines can still contain scientific surprises. A drug can be prescribed for millions of people for decades while researchers continue discovering new details about how it works. Metformin's long history does not mean its biology is completely understood.

For patients and researchers alike, the most important takeaway is therefore not alarm but curiosity. The 2025 findings suggest that metformin's story may extend beyond the liver and gut, with the brain potentially contributing to its effects on blood glucose. The next challenge is determining whether the pathway observed in mice operates in humans in the same way and how significant it is in real-world diabetes treatment. Until those questions are answered, the discovery remains an important piece of emerging science rather than a reason for patients to change established care.